Andrea Varga|Nofisat Ismaila|Kimberly H. Allison|William E. Barlow|Deborah Collyar|Senthil Damodaran|Norah L. Henry|Komal Jhaveri|Kevin Kalinsky|Nicole M. Kuderer|Anya M. Litvak|Erica L. Mayer|Lajos Pusztai|Rachel Raab|Antonio C. Wolff|Vered Stearns
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Institut Gustave Roussy|American Society of Clinical Oncology|Stanford University|Stanford Medicine|Cancer Research And Biostatistics|Advocates for Youth|The University of Texas MD Anderson Cancer Center|University of Michigan–Ann Arbor|Memorial Sloan Kettering Cancer Center|Cornell University|Emory University|Saint Barnabas Medical Center|Dana-Farber Cancer Institute|Yale Cancer Center|Johns Hopkins University|Johns Hopkins University
purpose update recommendations appropriate use breast cancer biomarker assay results guide adjuvant endocrine chemotherapy decisions earlystage breast cancer methods updated literature search identified randomized clinical trials prospectiveretrospective studies published january 2016 october 2021 outcomes interest included overall survival diseasefree recurrencefree survival expert panel members used informal consensus develop evidencebased recommendations results search identified 24 studies informing evidence base recommendations clinicians may use onco type dx mammaprint breast cancer index bci endopredict guide adjuvant endocrine chemotherapy patients postmenopausal age gt 50 years earlystage estrogen receptor erpositive human epidermal growth factor receptor 2 her2negative er her2 breast cancer nodenegative 13 positive nodes prosigna bci may used postmenopausal patients nodenegative er her2 breast cancer premenopausal patients clinicians may use onco type patients nodenegative er her2 breast cancer current data suggest premenopausal patients 13 positive nodes benefit chemotherapy regardless genomic assay result data use genomic tests guide adjuvant chemotherapy patients 4 positive nodes ki67 combined parameters immunohistochemistry 4 score may used postmenopausal patients without access genomic tests guide adjuvant therapy decisions bci may offered patients 03 positive nodes received 5 years endocrine therapy without evidence recurrence guide decisions extended endocrine therapy none assays recommended treatment guidance individuals her2positive triplenegative breast cancer treatment decisions also consider disease stage comorbidities patient preferences additional information available wwwascoorgbreastcancerguidelines